

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4383075/publications.pdf>

Version: 2024-02-01

10
papers

293
citations

1307366

7
h-index

1474057

9
g-index

10
all docs

10
docs citations

10
times ranked

571
citing authors

#	ARTICLE	IF	CITATIONS
1	A loss-of-function <i>IFNAR1</i> allele in Polynesia underlies severe viral diseases in homozygotes. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	28
2	Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE. <i>Scientific Reports</i> , 2021, 11, 21575.	1.6	4
3	Selective IL-1 activity on CD8 ⁺ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication. , 2021, 9, e003293.		9
4	Specific targeting of IL-1 ² activity to CD8+ T cells allows for safe use as a vaccine adjuvant. <i>Npj Vaccines</i> , 2020, 5, 64.	2.9	15
5	An Old Cytokine Against a New Virus?. <i>Journal of Interferon and Cytokine Research</i> , 2020, 40, 425-428.	0.5	9
6	Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor- α -based therapies. <i>EMBO Molecular Medicine</i> , 2020, 12, e11223.	3.3	33
7	Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice. <i>Journal of Autoimmunity</i> , 2019, 97, 70-76.	3.0	19
8	Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments. <i>Cancer Research</i> , 2018, 78, 463-474.	0.4	70
9	A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment. <i>Oncotimmunology</i> , 2018, 7, e1398876.	2.1	44
10	High efficiency cell-specific targeting of cytokine activity. <i>Nature Communications</i> , 2014, 5, 3016.	5.8	62